Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
NCT05955261Phase 2Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of venetoclax in acute myeloid leukemia (AML) (3 arms), sponsored by St. Jude Children's Research Hospital. Primary endpoints: Minimal residual disease-negativity rate at Day 29 and Incidence of death or unacceptable adverse event at 6 weeks. Started Jul 2023; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05955261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05955261.